698 related articles for article (PubMed ID: 14768038)
1. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative.
Ghiringhelli F; Larmonier N; Schmitt E; Parcellier A; Cathelin D; Garrido C; Chauffert B; Solary E; Bonnotte B; Martin F
Eur J Immunol; 2004 Feb; 34(2):336-44. PubMed ID: 14768038
[TBL] [Abstract][Full Text] [Related]
2. Complete regression of experimental solid tumors by combination LEC/chTNT-3 immunotherapy and CD25(+) T-cell depletion.
Li J; Hu P; Khawli LA; Epstein AL
Cancer Res; 2003 Dec; 63(23):8384-92. PubMed ID: 14679000
[TBL] [Abstract][Full Text] [Related]
3. Response of the immune system of mammary tumor-bearing rats to cyclophosphamide and soluble low-molecular-mass tumor-associated antigens: rate of lymphoid infiltration and distribution of T lymphocytes in tumors.
Ben-Hur H; Kossoy G; Zandbank J; Zusman I
Int J Mol Med; 2002 Apr; 9(4):425-30. PubMed ID: 11891540
[TBL] [Abstract][Full Text] [Related]
4. In vivo elimination of CD25+ regulatory T cells leads to tumor rejection of B16F10 melanoma, when combined with interleukin-12 gene transfer.
Nagai H; Horikawa T; Hara I; Fukunaga A; Oniki S; Oka M; Nishigori C; Ichihashi M
Exp Dermatol; 2004 Oct; 13(10):613-20. PubMed ID: 15447721
[TBL] [Abstract][Full Text] [Related]
5. Tumor-induced expansion of regulatory T cells by conversion of CD4+CD25- lymphocytes is thymus and proliferation independent.
Valzasina B; Piconese S; Guiducci C; Colombo MP
Cancer Res; 2006 Apr; 66(8):4488-95. PubMed ID: 16618776
[TBL] [Abstract][Full Text] [Related]
6. Distinct responses of two hepatocellular carcinoma cell lines of a similar origin to immunotherapies targeting regulatory or effector T cells.
Nagayama Y; Hase W; Motoyoshi Y; Saitoh O; Sogawa R; Nakao K
Oncol Rep; 2007 May; 17(5):1269-73. PubMed ID: 17390075
[TBL] [Abstract][Full Text] [Related]
7. TGF-beta1 production by CD4+ CD25+ regulatory T cells is not essential for suppression of intestinal inflammation.
Kullberg MC; Hay V; Cheever AW; Mamura M; Sher A; Letterio JJ; Shevach EM; Piccirillo CA
Eur J Immunol; 2005 Oct; 35(10):2886-95. PubMed ID: 16180248
[TBL] [Abstract][Full Text] [Related]
8. Tumor-localized ligation of CD3 and CD28 with systemic regulatory T-cell depletion induces potent innate and adaptive antitumor responses.
Lee CH; Chiang YH; Chang SE; Chong CL; Cheng BM; Roffler SR
Clin Cancer Res; 2009 Apr; 15(8):2756-66. PubMed ID: 19318495
[TBL] [Abstract][Full Text] [Related]
9. Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice.
Proietti E; Greco G; Garrone B; Baccarini S; Mauri C; Venditti M; Carlei D; Belardelli F
J Clin Invest; 1998 Jan; 101(2):429-41. PubMed ID: 9435316
[TBL] [Abstract][Full Text] [Related]
10. Identification of a CD4+CD25+ T cell subset committed in vivo to suppress antigen-specific T cell responses without additional stimulation.
Nolte-'t Hoen EN; Wagenaar-Hilbers JP; Boot EP; Lin CH; Arkesteijn GJ; van Eden W; Taams LS; Wauben MH
Eur J Immunol; 2004 Nov; 34(11):3016-27. PubMed ID: 15376196
[TBL] [Abstract][Full Text] [Related]
11. Successful adoptive immunotherapy with vaccine-sensitized T cells, despite no effect with vaccination alone in a weakly immunogenic tumor model.
Parviz M; Chin CS; Graham LJ; Miller C; Lee C; George K; Bear HD
Cancer Immunol Immunother; 2003 Dec; 52(12):739-50. PubMed ID: 12827306
[TBL] [Abstract][Full Text] [Related]
12. Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells.
Fecci PE; Sweeney AE; Grossi PM; Nair SK; Learn CA; Mitchell DA; Cui X; Cummings TJ; Bigner DD; Gilboa E; Sampson JH
Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4294-305. PubMed ID: 16857805
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of cytolytic T lymphocyte proliferation by autologous CD4+/CD25+ regulatory T cells in a colorectal carcinoma patient is mediated by transforming growth factor-beta.
Somasundaram R; Jacob L; Swoboda R; Caputo L; Song H; Basak S; Monos D; Peritt D; Marincola F; Cai D; Birebent B; Bloome E; Kim J; Berencsi K; Mastrangelo M; Herlyn D
Cancer Res; 2002 Sep; 62(18):5267-72. PubMed ID: 12234995
[TBL] [Abstract][Full Text] [Related]
14. Depletion of CD4+CD25+ regulatory T cells promotes a tumor-specific immune response in pancreas cancer-bearing mice.
Viehl CT; Moore TT; Liyanage UK; Frey DM; Ehlers JP; Eberlein TJ; Goedegebuure PS; Linehan DC
Ann Surg Oncol; 2006 Sep; 13(9):1252-8. PubMed ID: 16952047
[TBL] [Abstract][Full Text] [Related]
15. Activated CD4+ CD25+ T cells suppress antigen-specific CD4+ and CD8+ T cells but induce a suppressive phenotype only in CD4+ T cells.
Dieckmann D; Plöttner H; Dotterweich S; Schuler G
Immunology; 2005 Jul; 115(3):305-14. PubMed ID: 15946248
[TBL] [Abstract][Full Text] [Related]
16. Human CD4+ CD25+ regulatory T cells suppress NKT cell functions.
Azuma T; Takahashi T; Kunisato A; Kitamura T; Hirai H
Cancer Res; 2003 Aug; 63(15):4516-20. PubMed ID: 12907625
[TBL] [Abstract][Full Text] [Related]
17. Depletion of CD25+ regulatory cells uncovers immune responses to shared murine tumor rejection antigens.
Golgher D; Jones E; Powrie F; Elliott T; Gallimore A
Eur J Immunol; 2002 Nov; 32(11):3267-75. PubMed ID: 12555672
[TBL] [Abstract][Full Text] [Related]
18. Effects of cyclophosphamide and soluble tumor-associated antigens on lymphoid infiltration, proliferative activity and rate of apoptosis in chemically-induced rat mammary tumors.
Ben-Hur H; Kossoy G; Tendler Y; Kossoy N; Zusman I
In Vivo; 2002; 16(5):287-92. PubMed ID: 12494865
[TBL] [Abstract][Full Text] [Related]
19. The requirement of multimodal therapy (vaccine, local tumor radiation, and reduction of suppressor cells) to eliminate established tumors.
Kudo-Saito C; Schlom J; Camphausen K; Coleman CN; Hodge JW
Clin Cancer Res; 2005 Jun; 11(12):4533-44. PubMed ID: 15958639
[TBL] [Abstract][Full Text] [Related]
20. Immune compartmentalization of T cell subsets in chemically-induced breast cancer.
Fahmi T; Esendagli G; Yilmaz G; Kansu E; Guc D
Scand J Immunol; 2010 Oct; 72(4):339-48. PubMed ID: 20883319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
